A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms

Journal of Clinical Psychopharmacology
Bruce J KinonSamuel G Siris

Abstract

The objective of this study is to compare olanzapine with ziprasidone therapy in patients with schizophrenia or schizoaffective disorder and experiencing depressive symptoms. This randomized, double-blind, 24-week, fixed-dose study compared olanzapine (n = 202) and ziprasidone (n = 192) for patients with schizophrenia or schizoaffective disorder and experiencing prominent depressive symptoms. Outcome measures included change in Calgary Depression Scale for Schizophrenia (CDSS) score from baseline to 8 weeks (primary outcome) and changes in CDSS, Montgomery-Asberg Depression Rating Scales, Positive and Negative Syndrome Scale, and Global Assessment of Functioning (GAF) scores for 24 weeks. Statistical analyses included mixed-effects model repeated measures (primary analysis) and change from baseline to last observation carried forward (LOCF). At baseline, patients had moderate depressive symptoms (mean Montgomery-Asberg Depression Rating Scales total score, 27.3). For 8 weeks, patients treated with olanzapine or ziprasidone had significant improvements on CDSS. Treatment group differences were not statistically significant (P = 0.493, mixed-effects model repeated measures; P = 0.497, LOCF). For 24 weeks, olanzapine-treated patie...Continue Reading

References

Mar 1, 1988·The British Journal of Psychiatry : the Journal of Mental Science·D A Johnson
Feb 1, 1995·Schizophrenia Research·J P LindenmayerR B Hyman
Feb 1, 1994·Schizophrenia Research·D AddingtonE Maticka-Tyndale
Mar 31, 1999·Schizophrenia Bulletin·J R Sands, M Harrow
Aug 31, 2000·The American Journal of Psychiatry·S G Siris
Jul 13, 2001·Journal of Psychopharmacology·S G Siris
Apr 23, 2003·Biological Psychiatry·Craig H MallinckrodtGary D Tollefson
Jan 30, 2004·Diabetes Care·UNKNOWN American Diabetes AssociationUNKNOWN North American Association for the Study of Obesity
Aug 3, 2004·The American Journal of Psychiatry·Stephen R MarderSteven Shon
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Oct 4, 2005·The American Journal of Psychiatry·Alan BreierJohn M Kane

❮ Previous
Next ❯

Citations

May 27, 2010·Clinical Neuropharmacology·Sung-Wan KimJin-Sang Yoon
May 30, 2009·Diabetes, Obesity & Metabolism·Richard I G Holt, Robert C Peveler
Jan 9, 2008·BMC Psychiatry·Ilya LipkovichJohn P Houston
Dec 21, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel M GreenLeslie L Robison
Apr 26, 2014·PloS One·Maarten BakMarjan Drukker
Feb 22, 2011·Expert Opinion on Drug Safety·Leslie Citrome
Nov 6, 2008·Expert Opinion on Drug Safety·Joshua T Kantrowitz, Leslie Citrome
Mar 31, 2015·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Alkomiet HasanUNKNOWN WFSBP Task Force on Treatment Guidelines for Schizophrenia
Dec 14, 2012·Pharmacology, Biochemistry, and Behavior·Steve MannGary Remington
Mar 2, 2016·Drugs·Jean-Pierre Lindenmayer, Amandeep Kaur
Mar 10, 2009·Journal of Psychiatric Research·Gerald M ReavenAlan F Schatzberg
Feb 5, 2008·Schizophrenia Research·Rajiv TandonUNKNOWN Section of Pharmacopsychiatry, World Psychiatric Association
Jul 14, 2007·CNS Drug Reviews·William M Greenberg, Leslie Citrome
Apr 23, 2010·Journal of Clinical Pharmacology·Parminder S ChaggarSimon G Williams
Jun 7, 2014·Psychiatry and Clinical Neurosciences·Woo-Young JungSang-Heon Choi
Dec 9, 2014·Expert Opinion on Drug Metabolism & Toxicology·Roberto MandrioliLaura Mercolini
Jan 24, 2012·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Christopher N GrahamDavid Bruhn
Aug 25, 2016·Neurology and Therapy·Benedicto Crespo-FacorroJacqueline Mayoral-van Son
Jan 1, 2011·Journal of Central Nervous System Disease·Chiara MatteiStephen M Stahl
Sep 8, 2018·World Psychiatry : Official Journal of the World Psychiatric Association (WPA)·Maren CarbonChristoph U Correll

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here